SINGAPORE, Feb 26 (Bernama) -- Mitsubishi Tanabe Pharma Corporation
(TSE: 4508), and Singapore-based A. Menarini Asia-Pacific Holdings Pte
Ltd ("Menarini AP") have entered into a licensing agreement to
commercialize and promote SPEDRA™ (avanafil). Menarini AP will receive
exclusive licensing rights from Mitsubishi Tanabe Pharma Corporation to
market Avanafil in China, Hong Kong, Macao, Taiwan, Indonesia, Malaysia,
Philippines, Singapore, Thailand, Vietnam.
Menarini AP is a member of the Menarini Group, the world's largest
Italian biopharmaceutical company, and provides physicians and
healthcare professionals with medical and scientific information with
competence, correctness and the highest ethical standards in all its
work processes. Menarini Group has already been licensed to market this
product in over 40 European countries, plus Australia and New Zealand.
http://www.bernama.com/bernama/v8/newsindex.php?id=1219590
No comments:
Post a Comment